Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Vitamin K (Phylloquinone) is scientifically validated for the treatment and prevention of certain bleeding disorders, particularly those related to vitamin K deficiency. Vitamin K is essential for the synthesis of clotting factors II, VII, IX, and X in the liver. Without sufficient vitamin K, these factors are not properly carboxylated, resulting in impaired coagulation and an increased risk of bleeding, both internally and externally.

Clinical use of vitamin K is well established, especially in newborns (to prevent hemorrhagic disease of the newborn), in patients with vitamin K deficiency (due to malabsorption, chronic liver disease, or long-term use of antibiotics), and as an antidote to reverse the effects of warfarin and other vitamin K antagonists. The administration of vitamin K, usually by injection, rapidly restores the synthesis of functional clotting factors, thereby reducing bleeding risk. Numerous randomized controlled trials and clinical guidelines support this practice. For instance, the American Academy of Pediatrics and the World Health Organization recommend routine vitamin K prophylaxis for all newborns to prevent potentially life-threatening bleeding.

However, it is important to note that vitamin K is not effective for treating bleeding unrelated to vitamin K deficiency or antagonism (e.g., trauma in a person with normal vitamin K status). Nevertheless, its role in supporting hemostasis in deficiency states is clear and evidence-based, justifying its widespread medical use for these indications.

More about Vitamin K (Phylloquinone)
More about Bleeding (external)

Other ingredients used for Bleeding (external)

Other health conditions supported by Vitamin K (Phylloquinone)

Products containing Vitamin K (Phylloquinone)